$831 Million is the total value of Consonance Capital Management LP's 32 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 54.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $154,696,000 | +120.4% | 3,446,874 | +27.2% | 18.62% | +148.8% |
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $98,838,000 | +11.8% | 1,199,339 | -0.2% | 11.90% | +26.2% |
| TNDM | New | TANDEM DIABETES CARE INC | $95,377,000 | – | 979,226 | +100.0% | 11.48% | – |
| GMED | Buy | GLOBUS MED INCcl a | $84,118,000 | +135.8% | 1,084,979 | +87.6% | 10.12% | +166.3% |
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $67,630,000 | +159.9% | 1,647,497 | +83.7% | 8.14% | +193.4% |
| VSTM | Buy | VERASTEM INC | $55,352,000 | +100.1% | 13,600,014 | +21.4% | 6.66% | +125.9% |
| KROS | Sell | KEROS THERAPEUTICS INC | $37,708,000 | -31.2% | 887,885 | -0.3% | 4.54% | -22.3% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $31,819,000 | – | 409,301 | +100.0% | 3.83% | – |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $28,542,000 | -69.4% | 159,087 | -71.5% | 3.44% | -65.5% |
| AFMD | Sell | AFFIMED N V | $27,000,000 | -43.2% | 3,176,418 | -47.1% | 3.25% | -35.9% |
| GMDA | Sell | GAMIDA CELL LTD | $18,323,000 | -31.7% | 2,858,558 | -13.9% | 2.20% | -23.0% |
| CASI | Sell | CASI PHARMACEUTICALS INC | $15,999,000 | -36.8% | 10,321,956 | -2.1% | 1.92% | -28.6% |
| CFMS | Sell | CONFORMIS INC | $14,656,000 | +13.9% | 12,744,030 | -2.0% | 1.76% | +28.6% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $14,213,000 | -68.1% | 388,222 | -60.9% | 1.71% | -64.0% |
| NKTX | Sell | NKARTA INC | $13,940,000 | -25.7% | 439,876 | -22.9% | 1.68% | -16.1% |
| INFI | Sell | INFINITY PHARMACEUTICALS INC | $11,263,000 | -47.0% | 3,766,817 | -42.7% | 1.36% | -40.2% |
| ACET | Sell | ADICET BIO INC | $10,551,000 | -33.7% | 1,025,405 | -15.7% | 1.27% | -25.2% |
| CHFWU | CONSONANCE HFW ACQUISITION Cunit 99/99/9999 | $10,391,000 | +6.5% | 1,000,000 | 0.0% | 1.25% | +20.3% | |
| SIOX | Sell | SIO GENE THERAPIES INC | $8,108,000 | -2.5% | 2,969,987 | -6.8% | 0.98% | +10.0% |
| SLN | SILENCE THERAPEUTICS PLCads | $5,779,000 | +13.1% | 222,222 | 0.0% | 0.70% | +27.5% | |
| CLRB | Sell | CELLECTAR BIOSCIENCES INC | $4,656,000 | -29.0% | 3,913,000 | -4.0% | 0.56% | -19.9% |
| RACB | RESEARCH ALLIANCE CORP II | $3,032,000 | -1.4% | 300,000 | 0.0% | 0.36% | +11.3% | |
| JYAC | JIYA ACQUISITION CORP | $2,982,000 | +1.0% | 300,000 | 0.0% | 0.36% | +14.0% | |
| MSAC | New | MEDICUS SCIENCES ACQUISITION | $2,895,000 | – | 300,000 | +100.0% | 0.35% | – |
| CMAX | New | CAREMAX INC | $2,748,000 | – | 213,036 | +100.0% | 0.33% | – |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $2,680,000 | +2.4% | 250,000 | 0.0% | 0.32% | +15.8% | |
| BCTG | BCTG ACQUISITION CORP | $2,048,000 | +2.3% | 180,000 | 0.0% | 0.25% | +15.5% | |
| PANA | New | PANACEA ACQUISITION CORP II | $2,002,000 | – | 200,000 | +100.0% | 0.24% | – |
| TKNO | New | ALPHA TEKNOVA INC | $1,780,000 | – | 75,000 | +100.0% | 0.21% | – |
| HLXA | HELIX ACQUISITION CORP | $1,552,000 | +1.4% | 150,000 | 0.0% | 0.19% | +14.7% | |
| CMAXW | New | CAREMAX INC*w exp 06/08/202 | $217,000 | – | 45,960 | +100.0% | 0.03% | – |
| MSACW | New | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $34,000 | – | 33,331 | +100.0% | 0.00% | – |
| MSACU | Exit | MEDICUS SCIENCES ACQUISITIONunit 99/99/9999 | $0 | – | -300,000 | -100.0% | -0.32% | – |
| DFHTU | Exit | DEERFIELD HEALTHCARE TECH ACunit 07/16/2025 | $0 | – | -229,800 | -100.0% | -0.32% | – |
| IMGN | Exit | IMMUNOGEN INC | $0 | – | -703,790 | -100.0% | -0.61% | – |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -2,512,800 | -100.0% | -0.78% | – |
| STXS | Exit | STEREOTAXIS INC | $0 | – | -3,508,676 | -100.0% | -2.51% | – |
| ATRA | Exit | ATARA BIOTHERAPEUTICS INC | $0 | – | -1,669,293 | -100.0% | -2.56% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -790,197 | -100.0% | -2.67% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -460,000 | -100.0% | -3.24% | – |
| TPTX | Exit | TURNING POINT THERAPEUTICS I | $0 | – | -450,396 | -100.0% | -4.54% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -255,203 | -100.0% | -4.66% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -2,472,447 | -100.0% | -8.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.